Hutch News
Results per Page:
Extending efficacy for CAR T-cell therapies
Dr. Shivani Srivastava receives NCI MERIT Award to investigate how to improve engineered cancer immunotherapies against solid tumors through reservoirs of self-renewing immune cells
Scientists boost immune function in mice by mimicking natural renewal processes
New study identifies molecular players in ‘dead man’s switch’ that triggers key immune organ’s regeneration after damage
New computational method opens window into immune cell behavior
Approach links T-cell receptor genes to T-cell activity and function at single-cell resolution
Advances in blood disorders research continue despite COVID-19
Expanding use of CAR T-cell therapies, gene editing lead to insights at virtual annual meeting of the American Society of Hematology
Adoptive transfer of engineered T cells prolongs survival in preclinical ovarian cancer
From the Greenberg lab, Clinical Research Division, and the Vaccine and Infectious Disease Division
Failed Alzheimer’s drug boosts CAR T-cell therapy
Engineered immune cells get a helping hand in new clinical trial for multiple myeloma patients
WT1 T-cell Receptor Transduced T cells prevent AML relapse
From the Chapuis and Greenberg Labs, Clinical Research Division
5 questions with a cancer immunotherapy expert
Dr. Phil Greenberg to receive high honor for his contributions to the field
Good News: Fred Hutch joins coalition that seeks to increase transparency on life science career prospects
Celebrating faculty and staff achievements
Fred Hutch Statement Regarding the FDA Action on CTL019 Immunotherapy
Fred Hutch expert comments on FDA approval of new Novartis immunotherapy drug CTL019 — August 30, 2017